Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIRT plus XELOX, bevacizumab, and atezolizumab in liver-dominant metastatic colorectal cancer
2019-002400-40Phase 2Active
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab, bevacizumab, capecitabine and oxaliplatin in colorectal cancer (CRC), sponsored by Fédération Francophone de Cancérologie Digestive. Primary endpoint: Progression-free survival at 9 months. Started Apr 2020; status: active.
02
Drugs
atezolizumabbevacizumabcapecitabineoxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2019-002400-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002400-40.